Compare Stocks

Enter up to five stock symbols separated by a comma or space (ex. BAC,WFC,JPM,LON:BARC).

Date Range:

	Haemonetics	Inspire Medical Systems	Integra LifeSciences	Inari Medical	Tandem Diabetes Care
Symbol	NYSE:HAE	NYSE:INSP	NASDAQ:IART	NASDAQ:NARI	NASDAQ:TNDM
Price Information
Current Price	$52.00	$166.80	$70.97	$81.97	$76.81
52 Week Range	Buy	Buy	Hold	Buy	Buy
MarketRank™
Overall Score	2.1	1.2	1.4	1.5	1.6
Analysis Score	4.3	1.3	1.2	4.4	3.4
Community Score	2.2	2.4	2.2	3.3	2.5
Dividend Score	0.0	0.0	0.0	0.0	0.0
Ownership Score	1.7	1.7	1.7	0.0	1.7
Earnings & Valuation Score	2.5	0.6	1.9	0.0	0.6
Analyst Ratings
Consensus Recommendation	Buy	Buy	Hold	Buy	Buy
Consensus Price Target	$115.40	$177.70	$70.90	$117.17	$121.17
% Upside from Price Target	121.92% upside	6.53% upside	-0.10% downside	42.94% upside	57.75% upside
Trade Information
Market Cap	$3.04 billion	$4.65 billion	$5.91 billion	$4.22 billion	$4.99 billion
Beta	0.56	1.71	1.26	N/A	0.31
Average Volume	658,448	231,668	375,918	580,587	767,872
Sales & Book Value
Annual Revenue	$988.48 million	$82.05 million	$1.52 billion	N/A	$362.30 million
Price / Sales	2.67	55.32	3.95	N/A	13.28
Cashflow	$2.30 per share	N/A	$4.44 per share	N/A	N/A
Price / Cash	22.59	N/A	16.00	N/A	N/A
Book Value	$11.67 per share	$5.81 per share	$16.50 per share	N/A	$3.30 per share
Price / Book	4.46	28.71	4.30	N/A	23.28
Profitability
Net Income	$76.53 million	$-33,240,000.00	$50.20 million	N/A	$-24,750,000.00
EPS	$3.31	($1.40)	$2.74	N/A	($0.22)
Trailing P/E Ratio	25.12	N/A	105.93	0.00	N/A
Forward P/E Ratio	14.81	N/A	24.47	N/A	N/A
P/E Growth	5.17	N/A	1.97	N/A	N/A
Net Margins	11.76%	-61.07%	4.10%	N/A	-11.10%
Return on Equity (ROE)	22.85%	-32.23%	14.26%	N/A	-10.98%
Return on Assets (ROA)	10.40%	-26.42%	5.77%	N/A	-5.59%
Dividend
Annual Payout	N/A	N/A	N/A	N/A	N/A
Dividend Yield	N/A	N/A	N/A	N/A	N/A
Three-Year Dividend Growth	N/A	N/A	N/A	N/A	N/A
Payout Ratio	N/A	N/A	N/A	N/A	N/A
Years of Consecutive Dividend Growth	N/A	N/A	N/A	N/A	N/A
Debt
Debt-to-Equity Ratio	0.44%	0.11%	1.08%	N/A	0.61%
Current Ratio	2.25%	14.67%	4.52%	13.92%	5.61%
Quick Ratio	1.34%	14.18%	3.31%	13.42%	4.94%
Ownership Information
Institutional Ownership Percentage	96.22%	96.30%	85.71%	17.77%	88.60%
Insider Ownership Percentage	1.63%	6.60%	4.30%	N/A	6.00%
Miscellaneous
Employees	3,004	341	3,700	456	1,500
Shares Outstanding	50.82 million	27.21 million	84.55 million	49.58 million	62.64 million
Next Earnings Date	5/13/2021 (Confirmed)	8/3/2021 (Estimated)	8/9/2021 (Estimated)	8/10/2021 (Estimated)	7/29/2021 (Estimated)
Optionable	Optionable	Optionable	Optionable	Not Optionable	Optionable

Source	Headline
	Tandem Diabetes Care (NASDAQ:TNDM) Issues FY 2021 Earnings Guidance americanbankingnews.com - May 12 at 11:06 AM
	Tandem Diabetes Care (NASDAQ:TNDM) Price Target Raised to $102.00 marketbeat.com - May 12 at 9:44 AM
	Tandem Diabetes Care (NASDAQ:TNDM) Given New $102.00 Price Target at SVB Leerink americanbankingnews.com - May 12 at 9:14 AM
	Robert W. Baird Stick to Their Hold Rating for Tandem Diabetes Care investing.com - May 9 at 8:39 AM
	Analysts Are Updating Their Tandem Diabetes Care, Inc. (NASDAQ:TNDM) Estimates After Its First-Quarter Results nasdaq.com - May 8 at 2:23 PM
	Tandem Diabetes Care (NASDAQ:TNDM) versus Inovio Pharmaceuticals (NASDAQ:INO) Financial Review americanbankingnews.com - May 8 at 11:50 AM
	Analysts Expect Tandem Diabetes Care, Inc. (NASDAQ:TNDM) Will Announce Quarterly Sales of $138.33 Million americanbankingnews.com - May 8 at 2:02 AM
	Tandem Diabetes Care, Inc. (TNDM) CEO John Sheridan on Q1 2021 Results - Earnings Call Transcript seekingalpha.com - May 7 at 1:46 PM
	-$0.09 EPS Expected for Tandem Diabetes Care, Inc. (NASDAQ:TNDM) This Quarter americanbankingnews.com - May 6 at 11:46 PM
	Tandem Diabetes Care (NASDAQ:TNDM) Announces Quarterly Earnings Results, Beats Expectations By $0.08 EPS americanbankingnews.com - May 6 at 4:28 PM
	SVB Leerink Raises Tandem Diabetes Care (NASDAQ:TNDM) Price Target to $102.00 americanbankingnews.com - May 6 at 10:13 AM
	Tandem Diabetes Care Inc (TNDM) Q1 2021 Earnings Call Transcript finance.yahoo.com - May 6 at 2:36 AM
	Tandem Diabetes Care (NASDAQ:TNDM) Releases FY 2021 Earnings Guidance americanbankingnews.com - May 5 at 10:14 PM
	Tandem Diabetes Care rises after hours on Street-beating Q1, raised guidance drugdeliverybusiness.com - May 5 at 9:32 PM
	Tandem Diabetes Care, Inc. (TNDM) Reports Q1 Loss, Tops Revenue Estimates finance.yahoo.com - May 5 at 9:32 PM
	Tandem Diabetes Care Announces First Quarter 2021 Financial Results and Updated Full Year 2021 Sales Guidance finance.yahoo.com - May 5 at 4:32 PM
	An Intrinsic Calculation For Tandem Diabetes Care, Inc. (NASDAQ:TNDM) Suggests It's 26% Undervalued finance.yahoo.com - May 4 at 7:07 PM
	Custom Pre-earnings Bullish Diagonal Trigger in Tandem Diabetes Care Inc cmlviz.com - May 2 at 1:48 PM
	Tandem Diabetes Care, Inc. (TNDM) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release finance.yahoo.com - April 28 at 6:20 PM
	Technical Short Put Spread Fade the Dip Trade and Trigger in Tandem Diabetes Care Inc cmlviz.com - April 24 at 12:04 AM
	Is TNDM Stock A Buy or Sell? finance.yahoo.com - April 20 at 6:32 PM
	-$0.15 EPS Expected for Tandem Diabetes Care, Inc. (NASDAQ:TNDM) This Quarter americanbankingnews.com - April 19 at 5:14 PM
	Tandem Diabetes Care Inc (TNDM) investing.com - April 18 at 6:39 PM
	Tandem Diabetes Care Stock Gives Every Indication Of Being Modestly Undervalued gurufocus.com - April 17 at 11:15 AM
	CeQur Raises $115 Million Series C5 Financing to Support Commercialization and Scale-Up of Automated Manufacturing for CeQur Simplicity Wearable Insulin-Delivery Device finance.yahoo.com - April 13 at 8:27 AM
	Tandem Diabetes Care to Announce First Quarter 2021 Financial Results on May 5, 2021 finance.yahoo.com - April 6 at 6:09 PM

Date	Company	Brokerage	Action
4/26/2021	Haemonetics	Barrington Research	Lower Price Target
4/26/2021	Haemonetics	Needham & Company LLC	Lower Price Target
4/26/2021	Haemonetics	Morgan Stanley	Reiterated Rating
4/19/2021	Haemonetics	CJS Securities	Downgrade
2/12/2021	Haemonetics	Raymond James	Boost Price Target
1/21/2021	Haemonetics	JMP Securities	Boost Price Target
5/5/2021	Inspire Medical Systems	Lake Street Capital	Boost Price Target
5/5/2021	Inspire Medical Systems	Piper Sandler	Boost Price Target
4/25/2021	Inspire Medical Systems	Robert W. Baird	Reiterated Rating
3/2/2021	Inspire Medical Systems	SVB Leerink	Boost Price Target
1/4/2021	Inspire Medical Systems	Bank of America	Downgrade
12/15/2020	Inspire Medical Systems	The Goldman Sachs Group	Downgrade
11/3/2020	Inspire Medical Systems	Wells Fargo & Company	Boost Price Target
11/3/2020	Inspire Medical Systems	Oppenheimer	Upgrade
9/22/2020	Inspire Medical Systems	JPMorgan Chase & Co.	Initiated Coverage
8/21/2020	Inspire Medical Systems	Stifel Nicolaus	Boost Price Target
4/29/2021	Integra LifeSciences	Citigroup	Boost Price Target
2/25/2021	Integra LifeSciences	Credit Suisse Group	Boost Price Target
1/19/2021	Integra LifeSciences	BTIG Research	Boost Price Target
1/6/2021	Integra LifeSciences	Truist Financial	Boost Price Target
8/11/2020	Integra LifeSciences	UBS Group	Boost Price Target
5/12/2021	Inari Medical	Canaccord Genuity	Boost Price Target
7/31/2020	Tandem Diabetes Care	Craig Hallum	Boost Price Target
7/31/2020	Tandem Diabetes Care	Guggenheim	Upgrade
7/7/2020	Tandem Diabetes Care	Cowen	Boost Price Target

(Data available from 5/13/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Comparison Ideas:

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Your Ultimate Investing Toolkit

Just $1.00 for your first month.

Compare Stocks

30 Days of MarketBeat All Access for $1.00

Resources

Premium Research Tools

Market Data and Calendars

Investing Education and Resources